Stevens-Johnson Syndrome is a medical emergency. When a doctor misdiagnoses it as something less serious — and the drug that caused it keeps being taken — the consequences can be catastrophic. This article explains how SJS misdiagnosis happens, why it matters legally, and what patients and families can do about it.
How SJS Gets Misdiagnosed
Stevens-Johnson Syndrome does not announce itself clearly. The earliest symptoms — fever, sore throat, fatigue, body aches — look identical to a dozen more common conditions. A patient who walks into an emergency room or urgent care clinic with those complaints is far more likely to be diagnosed with a viral illness, an upper respiratory infection, or a drug allergy than with SJS.
That is partly because SJS is rare. Most emergency physicians will see only a handful of cases in an entire career. But rarity does not excuse a missed diagnosis when the clinical signs are there. According to a review published in the American Journal of Clinical Dermatology, SJS and TEN are classified as "high risk, low prevalence" conditions — meaning the consequences of missing them are severe even though individual clinicians encounter them infrequently.
What SJS Is Commonly Confused With
The most frequent misdiagnoses of early SJS include:
- Viral illness or upper respiratory infection — Fever, malaise, and sore throat in the prodromal phase are nearly indistinguishable from a common cold or flu.
- Drug allergy or allergic reaction — A mild rash after starting a new medication is often attributed to a non-serious drug reaction.
- Erythema multiforme — A less severe skin condition that shares some visual similarities with early SJS but does not involve the same degree of epidermal detachment.
- Conjunctivitis — Ocular symptoms, which appear early in many SJS cases, may be treated as a simple eye infection without recognizing the systemic pattern.
- Staphylococcal scalded skin syndrome — Another blistering condition more common in children, which can be confused with SJS in pediatric presentations.
A published case study in PMC illustrates how this plays out in practice: a 46-year-old woman visited the emergency department three separate times over three weeks. The first visit resulted in a diagnosis of upper respiratory infection. The second, bilateral conjunctivitis. Only on her third visit — after her condition had significantly worsened — was she admitted and correctly diagnosed with SJS.
This is not an isolated case. Research cited by SJS Canada suggests that approximately one-third of patients referred to specialist centers with suspected SJS or TEN ultimately receive a different final diagnosis — meaning misidentification flows in both directions and accurate early recognition remains a systemic challenge.
Why Every Hour Matters
SJS is a condition where the timeline between first symptom and irreversible harm is measured in hours and days, not weeks. The single most important intervention is stopping the causative drug. Every dose taken after symptoms begin increases the severity of the reaction.
A review in the journal Dermatology and Therapy found that early withdrawal of the causative drug significantly decreases the risk of death. Mortality rates escalate sharply with the percentage of body surface area (BSA) affected:
- SJS (less than 10% BSA): 5–9% mortality
- SJS/TEN overlap (10–30% BSA): 19–29% mortality
- TEN (more than 30% BSA): up to 48% mortality
When a physician misdiagnoses early SJS as a viral illness and sends the patient home — often telling them to continue taking the very medication causing the reaction — the disease has time to progress from SJS to SJS/TEN overlap or full TEN. That progression is not inevitable. It is preventable. And when it happens because of a diagnostic failure, it is the foundation of a malpractice claim.
The SCORTEN prognostic scoring system, widely used in burn units and dermatology, confirms that BSA involvement is the primary driver of acute mortality risk. A patient whose disease could have been caught at 5% BSA but was not diagnosed until 25% BSA has suffered a fundamentally different — and far more dangerous — injury.
The Standard of Care for Diagnosing SJS
The medical standard of care is the benchmark against which a physician's actions are measured in a malpractice case. For SJS, the standard of care has been defined by the American Academy of Dermatology, the American Burn Association, and in clinical literature published in peer-reviewed journals.
The standard requires:
-
Medication history review. Any patient presenting with rash, mucosal involvement, and fever should be asked about recent medication changes. The most commonly implicated drugs — anticonvulsants like carbamazepine and lamotrigine, allopurinol, sulfonamide antibiotics, and nevirapine — are well-documented in the literature.
-
High index of clinical suspicion. When a patient presents with fever above 102°F, a macular rash involving the trunk and face, mucosal erosions, and a recent history of new medication use, SJS must be in the differential diagnosis. Waiting for full-thickness skin detachment before considering SJS is a failure of clinical reasoning, not a reasonable exercise of medical judgment.
-
Immediate drug withdrawal. If SJS is suspected, the causative drug must be stopped immediately. This is not a decision that should wait for biopsy confirmation or specialist consultation.
-
Dermatology consultation and transfer. The patient should be evaluated by a dermatologist and, in significant cases, transferred to a burn unit or ICU. The American Burn Association's referral guidelines establish that SJS and TEN patients benefit from the same specialized wound care and fluid management provided to burn patients.
A physician who fails to take a medication history, does not consider SJS in the differential, sends the patient home on the same drug, or delays transfer to appropriate care has deviated from this standard. That deviation is the legal definition of negligence.
Who Can Be Held Liable for a Missed SJS Diagnosis
Misdiagnosis liability in an SJS case can extend to multiple parties, depending on who saw the patient and when.
Emergency Room Physicians
ER doctors are often the first to evaluate an SJS patient. When a patient presents with the classic triad — fever, rash, and recent new medication — and the ER physician diagnoses a viral illness or drug allergy without further investigation, that physician may be liable for the downstream consequences. This is especially true when the patient returns to the same ER with worsening symptoms and is again sent home.
Hospitalists and Attending Physicians
If a patient is admitted but the attending physician does not order a dermatology consult, does not stop the suspected medication, or delays transfer to a burn unit, the hospitalist or attending may bear liability for the progression that occurred during that delay.
Urgent Care Providers
Urgent care clinics increasingly serve as the first point of contact for patients with emerging symptoms. The standard of care applies in this setting too. An urgent care provider who attributes a worsening rash with mucosal involvement to a minor allergic reaction — and tells the patient to continue the medication — has potentially breached the standard of care.
Hospital Systems
In addition to individual physician liability, the hospital or clinic may be liable as an institution. If the facility lacked protocols for recognizing drug-induced skin reactions, failed to train staff on SJS screening, or did not have a process for dermatology referral in cases involving mucosal blistering, the system itself contributed to the diagnostic failure.
This is important to understand: SJS malpractice is not limited to the doctor who prescribed the original drug. It can include every provider who had the opportunity to recognize the reaction and failed to act. An experienced SJS attorney can evaluate the entire chain of care to identify every viable defendant in your case.
How Misdiagnosis Changes the Legal Case
A delayed SJS diagnosis does not just worsen the medical outcome. It strengthens the legal claim in specific ways.
Causation Becomes Clearer
In a standard SJS malpractice case involving prescribing negligence, the defense may argue that SJS can occur even when a drug is properly prescribed. That argument is harder to make when the negligence is diagnostic. If the patient presented with recognizable SJS symptoms and the provider failed to act, the connection between the failure and the resulting harm is direct and difficult to dispute.
Damages Are Higher
A patient diagnosed promptly with SJS — drug stopped, transferred to a burn unit, treated aggressively — may recover with limited scarring and manageable complications. A patient whose SJS was missed and progressed to TEN may face permanent vision loss, disfiguring scarring, chronic pain, organ damage, and months of hospitalization. The difference in outcomes is directly traceable to the diagnostic delay.
Multiple Defendants May Apply
When SJS is missed across multiple clinical encounters — as in the case of the patient who visited the ER three times — each provider who had the opportunity to diagnose and did not may be independently liable. This can significantly increase the available recovery for the patient.
Genetic Screening Failures and Misdiagnosis
Some patients should never have been prescribed the drug that caused their SJS in the first place. For these patients, the misdiagnosis is the second failure in a chain that began with a prescribing error.
The most well-documented example involves the HLA-B*1502 genetic variant. Since 2007, the FDA has required that providers test patients of Han Chinese, Thai, Filipino, Malaysian, and other Southeast Asian descent for this allele before prescribing carbamazepine. Patients who carry HLA-B*1502 have a dramatically elevated risk of developing SJS from carbamazepine.
When a provider skips this test and the patient develops SJS, the prescribing failure and the diagnostic failure may be pursued as separate but related claims. If the same provider also missed the early signs of SJS, both failures compound the harm — and the legal exposure.
For a deeper discussion of how genetic screening obligations factor into SJS cases, see our comprehensive SJS legal guide.
What to Do If You Believe SJS Was Misdiagnosed
If you or a family member developed SJS or TEN, and you believe the diagnosis was delayed or incorrect, there are specific steps you should take.
Preserve your medical records. Request complete records from every facility that treated you — including the visits where SJS was not diagnosed. The records from the initial misdiagnosis are often the most important evidence in the case.
Document the timeline. Write down when symptoms first appeared, when you sought medical care, what you were told at each visit, and when the correct diagnosis was finally made. The gap between first presentation and correct diagnosis is central to the legal theory.
Do not delay. Every state has a statute of limitations that restricts how long you have to file a medical malpractice claim. In many states, the clock begins running from the date of injury or the date you knew (or should have known) about the misdiagnosis. Some states also require a pre-suit expert affidavit. For a state-by-state overview of SJS litigation deadlines, see our SJS legal guide's statute of limitations section.
Consult an SJS attorney. SJS cases require attorneys who understand both the pharmacology of high-risk drugs and the clinical standards for diagnosing drug-induced skin reactions. Childers, Schlueter & Smith is one of the few firms in the United States with dedicated SJS litigation experience, including tried verdicts. Initial consultations are free and confidential.
When Both Misdiagnosis and Prescribing Negligence Apply
In many SJS cases, the diagnostic failure is only part of the story. The prescribing decision itself may also have been negligent — the drug was started too quickly, the patient was not counseled on warning signs, or a required genetic test was not performed.
When both theories apply, the case is stronger than either theory alone. The prescribing error created the risk. The diagnostic error allowed the risk to become catastrophic.
This overlap is why SJS cases often involve product liability claims alongside malpractice claims. If the drug manufacturer provided inadequate labeling or failed to update prescribing information when new safety data emerged, the manufacturer may be an additional defendant. An attorney experienced in SJS litigation will evaluate all potential theories — malpractice, product liability, and pharmacy liability — to identify the strongest path to recovery.
This article is part of The Legal Examiner's Stevens-Johnson Syndrome legal resource center. It was produced in collaboration with Childers, Schlueter & Smith and reviewed by attorneys with dedicated SJS litigation experience. This article provides general legal information and does not constitute legal advice or create an attorney-client relationship.
